Inhibition of the expression of a gene called NHERF-1 may be useful in the treatment of deadly brain cancers in the class glioblastoma multiforme (GBM), according to findings published by researchers at the Translational Genomics Research Institute (TGen) and Barrow Neurological Institute in the April issue of Neoplasia. "Our findings suggest a novel mechanism defining NHERF-1 as a 'molecular switch' that regulates the GBM tumor cell's ability to migrate or divide,'' said Dr. Kerri Kislin, the lead author of the study. The findings will be presented during the AACR annual meeting April 18-22. [Press release]Login Or Register To Read Full Story